Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATXS 11.04.2024

Full Press ReleaseSEC FilingsOur ATXS Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
  • 01.13.2025 - Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE
  • 01.03.2025 - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON--(BUSINESS WIRE)--Nov. 4, 2024--Astria Therapeutics, Inc.(Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 210,000 shares of Astria’s common stock onNovember 1, 2024under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee ofAstria.

The options were granted as an inducement material to two employees entering into employment withAstriain accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of$11.32, which is equal to the closing price of Astria’s common stock onNovember 1, 2024(the “Grant Date”), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee’s employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee’s continued employment withAstriaon such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

AboutAstria Therapeutics:

Astria Therapeuticsis a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website,www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241104640225/en/

Astria:Investor Relations and Media:Elizabeth Higginsinvestors@astriatx.com

Source:Astria Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com